November 1, 2009 / 11:51 PM / 10 years ago

Takeda, Amylin to co-develop obesity drugs

TOKYO, Nov 2 (Reuters) - Japan’s Takeda Pharmaceutical (4502.T) and U.S. Amylin Pharmaceuticals AMLN.O said on Monday they have agreed to co-develop drugs to treat obesity.

Amylin will receive a one-time up-front payment of $75 million from Takeda, the companies said in a joint statement. (Reporting by Taiga Uranaka)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below